mergers & acquisition
DESCRIPTION
TRANSCRIPT
Dr Sheeba Kapil 1
Mergers & Acquisition
Dr Sheeba Kapil 2
Most of M&A fail ?
Pursue them when they make sense Deals should be above average Easier said than done‼ Why pursued by cos?
Maximum value is given by Market to acquisition deals as compared to alliances/sale
Dr Sheeba KapilDr Sheeba Kapil 33
Stock Market Premium %
2.65
0.26
0.2
-3.1
Dr Sheeba Kapil 4
Market prefers deals that are part of an “expansionist program”,
consolidation, new geographic regions, adding new distribution channels, for
existing products & services
Market less tolerant of “transformative deals” that move cos into new lines of business,
remove a chunk of an otherwise healthy business portfolio’
Dr Sheeba Kapil 5
MARKET PREFERSDEALS
CONSOLIDATING
NEW GEOGRAPHIC REGION
ADD NEW DISTRIBUTION
CHANNEL
EXPANSIONPROGRAM
TRANSFORMATIVE NATURE
Dr Sheeba Kapil 6
MARKET VALUES
ACQUISITION OTHERS
Heineken 1999-00, increase in net turnover: new acquisitions 8%, increased sales 2%, higher sales price/mix 2%, improved exch rates 2%
2003:04Europe :BBAG: Brau Union: Largest Brewer In Central EuropeChina: Fraser & Neave: Heineken Asia Pacific Breweries China, Acquired Interest Guangdong Brewery HoldingsAustralia: JV Lion Nathan Australia: Heineken Lion Nathan
Dr Sheeba Kapil 7
SABMILLER
African brewer:
Int. conglomerate
International acquisitionsUS, central Europe, Africa,
Asia
2000: Narang Breweries : Lucknow2001: Mysore Breweries Ltd, Rochees Breweries Ltd
2003: Shaw Wallace: Beer Division (Strong Brand Haywards)2006: Foster’s India: Maharashtra
Mohan Meakin’s Acquisition Attempt
Dr Sheeba Kapil 8
Dr Sheeba Kapil 9
Cash deals received more favorable market reaction than stock deals
(trading & signaling effect )
Overpayment in the deals has reduced
Dr Sheeba Kapil 10
Positive correlation announcement effects & long run value creation
Record level in announced M&A
DVA- total value deals create
POP- proportion of cos overpaying
Dr Sheeba Kapil 11
DVA
Measures aggregate value change at time of announcement (both cos)
as a % of transaction’s value
Market’s assessment of value to be created
Dr Sheeba Kapil 12
POP
Proportion of transactions in which the initial share price reaction negative
Acquirer overpaid
Dr Sheeba Kapil 13
1) Millman and Grey show that “…83% of mergers produce no benefit whatsoever to shareholders”
2) Sirower finds 60-70% of acquisitions failing to produce positive returns.
Dr Sheeba Kapil 14
TREND
LOWER DEAL PREMIUM
CASH DEAL PREFERRED
SECTORAL STUDY YET TO BE DONE
DVA POP
2006: 6.1% Av1996-06: 3.4%
57% 200665% (97-00)
Pure cash deal: 13.7% PC deal: 49% of Acq overpay
Pure stock deal: -3.3% PS deal: 69% of Acq overpay
Dr Sheeba Kapil 15
POPULAR TERMINOLOGIES
Hostile take over
Dawn raid – UK
Saturday night special – US
White knight
Dr Sheeba Kapil 16
Shark repellent
Golden parachute Greenmail/ goodbye kiss Macaroni defense Bank check preferred stock Poison pill (flip in PP, flip over PP) Lady macbeth Bankmail
Dr Sheeba Kapil 17
Types of M&A
Merger
A transaction where two firms agree to integrate their operations on a
relatively coequal basis because they have resources and capabilities that
together may create a stronger competitive advantage
Dr Sheeba Kapil 18
the 2 firms combine all assets & liabilities
Acquirer = target
Usually take a new name
JP Morgan/Chase Manhattan becomes JP Morgan Chase
Exxon and Mobil becomes Exxon-Mobil
Dr Sheeba Kapil 19
Target firm shares disappear Target shareholders get either
1) Shares in new firm2) Cash
Exchange Ratio = # shares in new firm given for each share of Target firm
Ex) # target = 250 million & ER = 1.25 # New = 1.25 x 250 M = 312.5 M
Buyer firm shares are kept as shares in new firm ( in effect their ER = 1).
Dr Sheeba Kapil 20
Combination of 2 firms- only one firm's identity survives
Statutory merger- in accordance with statutes of state in which it is incorpt.
Subsidiary merger- target becomes subsidiary of parent like GM & EDS
Horizontal merger
Vertical merger
Dr Sheeba Kapil 21
Acquisition
A transaction where one firm buys another firm with the intent of more effectively using a core competence
by making the acquired firm a subsidiary within its portfolio of
businesses
Dr Sheeba Kapil 22
Takeover
An acquisition where the target firm did not solicit the bid of the acquiring firm
IBM’s acquisition of Lotus in 1995; Oracle’s bid for PeopleSoft in 2003
Dr Sheeba Kapil 23
M&A Jargons
Corporate restructuring (asset/ financial)
Types
Operational - downsizing/downscoping
Financial – debt/equity (leverage effect )
Dr Sheeba Kapil 24
Amalgamation
Section 2(1B)
“Amalgamation”, in relation to companies, means the merger of one or more companies with another company or the merger of two or more companies to form one company…….”
Mergers – Not defined under the Income-tax Act, 1961. However, in common parlance, merger means
combination of two or more commercial organizations into one
Dr Sheeba Kapil 25
Conditions
All properties to be transferred to the amalgamated company
All liabilities to be transferred to the amalgamated company
Shareholders holding at least 3/4th in value of shares of the amalgamating company should become shareholders of the amalgamated company
Dr Sheeba Kapil 26
Types of mergers
Dr Sheeba Kapil 27
Horizontal Merger
Results in the consolidation of firms that are direct rivals- i.e. sell substitutable
products within overlapping geographical markets
Increase mkt powerIncrease eff gain (economies of scale,
rationalization)
Dr Sheeba Kapil 28
Contd….
Two firm same industry Seek economies of scale (BP & Amoco expected to save $2 bn p.a.
from operations) huge challenge of integration (Exxon & mobil, Helene-Curtis and unilever)
Dr Sheeba Kapil 29
Kuhn & motto (1999)
Increases prices, decreases consumer surplus
Always benefits the merging firm Increases outsider’s profits Increases producer surplus Reduces net welfare
Dr Sheeba Kapil 30
Vertical mergers
1. Two firms participate at difft stages of production or value chain
2. cos do not own operations in major segment of value chain
Forward integration- Merck-medcoBackward integration- Chevron’s oil- gulf oil,
America online- mapquest
Dr Sheeba Kapil 31
Conglomerate merger Consolidated firms may sell related products, share
marketing & distribution channels & production processes, or they may be wholly unrelated
Ciba-Geigy (contact lens, Ritalin, Maalox) & Sandoz(Gerber Baby Food, Ovaltine) - Novartis
US steel- marathon oil = USX AOL- time Warner PepsiCo- pizza hut Citicorp- travelers insurance P&G & clorox Cardinal healthcare - allegiance
Dr Sheeba Kapil 32
Product extension in conglomerate
Involve firms that sell non competing products use related marketing channels of production processes
Citicorp – travelers insurance
Pepsico – pizza hut
Dr Sheeba Kapil 33
Market extension
Join together firms that sell competing products in separate geographical
markets
Time warner- TCI SBC communications- pacific telesis
Dr Sheeba Kapil 34
Pure conglomerate
Such merger unites firms that have no obvious relationship of any kind
AT&T – hartford insuranceBankcorp of America- Hughes
electronicsR J Reynolds- burmah oil & gas
Dr Sheeba Kapil 35
Participants
Investment bankers – strategic & tactical advice Screen potential buyers & sellers Contact & negotiate Valuation Deal structuringGoldman Sachs (40%), Morgan
Stanley (26%), Merill Lynch (22%)
Dr Sheeba Kapil 36
LAWYERS Thomson financial securities data
corporation Sherman & sterling, meagher & flom Skadden Simpson thatcher & barlet Nishith Desai Associates
Dr Sheeba Kapil 37
Accountants
Tax structure Due diligence
Proxy solicitors
Georgeson & co D F king & co
Dr Sheeba Kapil 38
Reasons for AcquisitionsReasons for AcquisitionsReasons for AcquisitionsReasons for Acquisitions
Increased Market PowerIncreased Market PowerAcquisition intended to reduce the competitive balance of Acquisition intended to reduce the competitive balance of the industrythe industry
Overcome Barriers to EntryOvercome Barriers to EntryAcquisitions overcome costly barriers to entry which may make Acquisitions overcome costly barriers to entry which may make “start-ups” economically unattractive“start-ups” economically unattractive
Dr Sheeba Kapil 39
Increased Speed to MarketIncreased Speed to MarketClosely related to Barriers to Entry, allows market entry Closely related to Barriers to Entry, allows market entry in a more timely fashionin a more timely fashion
DiversificationDiversification
Quick way to move into businesses when firm currently lacks Quick way to move into businesses when firm currently lacks experience and depth in industryexperience and depth in industry
Reshaping Competitive ScopeReshaping Competitive ScopeReshaping Competitive ScopeReshaping Competitive ScopeFirms may use acquisitions to restrict its dependence on a Firms may use acquisitions to restrict its dependence on a single or a few products or marketssingle or a few products or markets
Dr Sheeba Kapil 40
Buying established businesses reduces risk of start-up Buying established businesses reduces risk of start-up venturesventures
Lower Cost and Risk of New Product DevelopmentLower Cost and Risk of New Product Development
Dr Sheeba Kapil 41
Problems with M&A
Only financial team (organizational team) Integration problem Inadequate evaluation of target Large amt debt Fail to achieve synergy Overly diversified
Dr Sheeba KapilDr Sheeba Kapil 4242
CASE EXAMPLE CASE EXAMPLE
Trend Indian Pharma sectorTrend Indian Pharma sector
The key feature of M&A activity has The key feature of M&A activity has been consolidation of indigenous been consolidation of indigenous
drug manufacturersdrug manufacturers
Dr Sheeba KapilDr Sheeba Kapil 4343
The Indian Pharmaceutical Sector - The Indian Pharmaceutical Sector - largest amongst the developing nations. largest amongst the developing nations.
In the organized sector of the Indian In the organized sector of the Indian Pharmaceutical industry there are about Pharmaceutical industry there are about 250-300 companies, controlling about 250-300 companies, controlling about 70% of the total output in value terms70% of the total output in value terms
The top 10 players accounting for one The top 10 players accounting for one third of the total market. third of the total market.
Dr Sheeba KapilDr Sheeba Kapil 4444
Indian pharmaceuticals market is Indian pharmaceuticals market is expected to expand to US$ 25 billion expected to expand to US$ 25 billion by 2010. by 2010.
The domestic industry is fragmented The domestic industry is fragmented with over 4,000 manufacturing units. with over 4,000 manufacturing units.
In such a scenario, consolidation is In such a scenario, consolidation is the only answer to survive in the the only answer to survive in the post patent regime post patent regime
Dr Sheeba KapilDr Sheeba Kapil 4545
The Indian pharma industry is known forThe Indian pharma industry is known for
superior biotech and drug synthesis superior biotech and drug synthesis skillsskills
generics, generics, cost-effectiveness and cost-effectiveness and competitiveness competitiveness high quality high quality vertically integrated manufacturing vertically integrated manufacturing
assets,assets, differentiated business modelsdifferentiated business modelsthat give it an edge that give it an edge
Dr Sheeba KapilDr Sheeba Kapil 4646
Dr Sheeba KapilDr Sheeba Kapil 4747
Reasons for M&AReasons for M&A
The lack of (R&D) productivity, The lack of (R&D) productivity, expiring patents, expiring patents, generic competition andgeneric competition and high profile product recalls high profile product recalls easy availability of capital and easy availability of capital and increased global interest in the increased global interest in the
pharmaceutical and biotech industry pharmaceutical and biotech industry
Dr Sheeba KapilDr Sheeba Kapil 4848
Reasons for Indian M&AReasons for Indian M&A Build critical mass in terms of marketing, Build critical mass in terms of marketing,
manufacturing and research manufacturing and research infrastructure infrastructure
Establish front end presence Establish front end presence Diversification into new areas: Tap other Diversification into new areas: Tap other
geographies / therapeutic segments / geographies / therapeutic segments / customers to enhance product life cycle customers to enhance product life cycle and build synergies for new products and build synergies for new products
Enhance product, technology and Enhance product, technology and intellectual property portfolio intellectual property portfolio
Catapulting market share Catapulting market share
Dr Sheeba KapilDr Sheeba Kapil 4949
The total Indian Pharmaceutical The total Indian Pharmaceutical Market is valued at US$ 8790 million Market is valued at US$ 8790 million with a growth rate of 8%. with a growth rate of 8%.
The market is predominantly a The market is predominantly a branded generic market branded generic market
Dr Sheeba KapilDr Sheeba Kapil 5050
Company Company RevRev % foreign sales % foreign sales
All All Foreign Foreign
North North America America
Europe Europe
RanbaxyRanbaxy 11741174 79%79% 36%36% 16%16%Cipla Cipla 539539 45%45% 1515 99Dr reddy’s labDr reddy’s lab 422422 65%65% 2222 1515Aurobindo pharma Aurobindo pharma 307307 11%11% NaNa NaNaNicholas piramal Nicholas piramal 276276 13%13% NaNa NaNaSun pharmaSun pharma 270270 13%13% NaNa NaNaWockhardt ltdWockhardt ltd 269269 60%60% 50% combined50% combinedLupin Lupin 263263 48%48% Na Na NaNa
Cadila ph.Cadila ph. 231231 25%25% Na Na NaNa